Kyle Griffin @kylegriffin1
FDA release: "The FDA continues to recommend that the designs of ongoing randomized clinical trials of COVID-19 convalescent plasma ... remain unaltered, as COVID-19 convalescent plasma does not yet represent a new standard of care based on the current available evidence." — PolitiTweet.org